Axsome Therapeutics, Inc.
AXSM
$148.98
$1.170.79%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.55% | 19.26% | 20.69% | -15.96% | 18.58% |
| Total Depreciation and Amortization | 7.35% | 5.30% | 2.89% | 0.58% | 3.41% |
| Total Amortization of Deferred Charges | -50.16% | -52.47% | -5.79% | 5.36% | 4.84% |
| Total Other Non-Cash Items | 35.16% | 16.81% | -29.41% | -13.30% | 61.09% |
| Change in Net Operating Assets | 161.29% | -41.21% | -179.30% | 154.61% | -78.03% |
| Cash from Operations | 103.23% | 25.25% | -65.54% | -40.64% | 38.12% |
| Capital Expenditure | -346.15% | 96.15% | -1,026.67% | 66.67% | -73.08% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -346.15% | 96.15% | -1,026.67% | 66.67% | -73.08% |
| Total Debt Issued | -63.16% | -- | -- | -- | -- |
| Total Debt Repaid | 63.29% | -47,906.48% | -21.52% | -6.11% | -67.20% |
| Issuance of Common Stock | -42.50% | 20.74% | 108.83% | -47.39% | 85.45% |
| Repurchase of Common Stock | 5.18% | 79.52% | -713.51% | -12.68% | 64.38% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 57.60% | -137.42% | -8.86% | -11.72% | -4.21% |
| Cash from Financing | -38.43% | 18.01% | 105.49% | -53.15% | 111.47% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 956.79% | 114.58% | -20.48% | -202.60% | 174.02% |